AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug

TrenibotE is simply a first-in-class botulinum neurotoxin serotype E characterized by a accelerated onset of enactment arsenic aboriginal arsenic 8 hours aft medication (the earliest appraisal time) and a abbreviated duration of effect of 2-3 weeks.

In April 2025, the U.S.-based large-cap cause shaper submitted the FDA exertion for TrenibotE for moderate to terrible glabellar lines (frown lines).

On Wednesday, AbbVie announced a $1.4 cardinal concern to physique a pharmaceutical manufacturing field successful North Carolina.

The field volition integrate precocious manufacturing and laboratory technologies with artificial quality (AI) to enactment the accumulation of AbbVie’s immunology, neuroscience, and oncology medicines.

See Also: Avoid the #1 Investing Mistake: How Your ‘Safe' Holdings Could Be Costing You Big Time

Construction volition statesman this year, with completion expected by the extremity of 2028.

The task is portion of the company’s $100 cardinal committedness to U.S. R&D and superior investments, including manufacturing, implicit the adjacent decade.

The archetypal signifier of operation volition see small-volume parenteral (SVP) cause merchandise manufacturing facilities.

SVPs are sterile injectable pharmaceutical products with volumes typically little than 100 mL, including vials, prefilled cartridges, and prefilled syringes containing medicines for injection oregon infusion.

image via Shutterstock

Read Next: 

• Skip the Regrets: The Essential Retirement Tips Experts Wish Everyone Knew Earlier.

• Thinking astir ETFs? See what concern risks you should beryllium alert of earlier you buy.

Up Next: Transform your trading with Benzinga Edge's one-of-a-kind marketplace commercialized ideas and tools. Click present to entree unsocial insights that tin acceptable you up successful today's competitory market.